About us
We’re developing novel biopharmaceutical treatments that target the underlying mechanisms of brain-related conditions to shift the paradigm of neuropsychiatric care. Urgency drives our commitment.
Our Vision
We aspire to restore the lives of those with challenging neuropsychiatric conditions.
Our Mission
To create treatments for debilitating neuropsychiatric conditions by developing transformative biopharmaceuticals to address unmet medical needs.
Our Commitment
As a Public Benefit Corporation, we’re committed to creating transformative biopharmaceutical treatments for brain-related conditions. In recognition of the traditional knowledge and cultural significance of the iboga alkaloids, we have established “Healing Forward. Giving Back.” Each year, we will support educational initiatives in collaboration with 501©(3) organizations working within Indigenous communities to preserve natural resources and foster sustainable growth.
The iboga alkaloids and their uses are investigational and have not been approved by the U.S. Food and Drug Administration (FDA). This information is presented only for the purpose of providing a general overview and should not be construed as a recommendation for use, or FDA approval.